Seattle Genetics announced FDA approval for Brentuximab Vedotin (Adcetris) in combination with chemotherapy for peripheral T-cell Lymphoma, based on the ECHELON-2 (SGN35-014) study conducted in part at Stanford by the Advani team members. For more information please see the press release.

Congratulations to Jessica, Sipra, Thu and the rest of the team for their contribution to the approval of treatment for this difficult to treat disease.